GlassScriptPhysician profile
Aaron D Doheny
NPI 1730532854
$14,410.80
in general payments reported to CMS, 2019-2025
69 companies · $3,632 in 2025
The $3,632 reported for 2025 was more than what 89% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $2,550 · 2023: $3,079 · 2024: $4,768 · 2025: $3,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $1,382 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,091.31 |
| Long Term Medical Supply Or Device Loan | $1,382.39 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,070.51 | 2022-2025 | |
| Janssen Biotech, INC. | $970.82 | 2021-2025 | Talvey, Darzalex, Erleada |
| Daiichi Sankyo INC. | $796.99 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $782.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $528.20 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Lilly USA, LLC | $522.70 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $509.52 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $492.65 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $465.63 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $392.11 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $379.66 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $302.36 | 2022-2025 | Opdivo, Krazati, Augtyro |
| Bayer Healthcare Pharmaceuticals INC. | $245.82 | 2022-2025 | |
| Glaxosmithkline, LLC. | $234.63 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $215.68 | 2022-2025 | Xtandi, Xospata, Cresemba |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.40 | 2023-2025 | |
| Celgene Corporation | $205.50 | 2022-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $197.29 | 2022-2025 | Phesgo, Venclexta, Itovebi |
| Stemline Therapeutics INC. | $192.94 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $187.50 | 2022-2023 | Imbruvica |
| Emd Serono, INC. | $182.55 | 2023-2024 | Bavencio, Tepmetko |
| Sobi, INC | $181.98 | 2022-2025 | |
| Kite Pharma, INC. | $146.07 | 2022-2025 | Yescarta |
| Tersera Therapeutics LLC | $141.56 | 2021-2025 | Zoladex |
| Seagen INC. | $141.09 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Alexion Pharmaceuticals, INC. | $137.39 | 2022-2025 | Ultomiris |
| Array Biopharma INC | $136.69 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmaessentia USA Corporation | $126.34 | 2024-2025 | Besremi |
| Springworks Therapeutics, INC. | $125.65 | 2024-2025 | Ogsiveo |
| Karyopharm Therapeutics INC. | $119.26 | 2023-2025 | Xpovio |
| Dendreon Pharmaceuticals LLC | $112.80 | 2024-2025 | Provenge |
| Amgen INC. | $110.63 | 2022-2023 | Lumakras, Nplate, Vectibix |
| Jazz Pharmaceuticals INC. | $110.07 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $109.81 | 2023-2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $107.57 | 2021-2025 | |
| Blueprint Medicines Corporation | $102.79 | 2022-2024 | Ayvakit |
| Puma Biotechnology, INC. | $94.19 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $91.96 | 2023-2025 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $89.32 | 2024-2025 | Monoferric, Cosela |
| Taiho Oncology, INC. | $84.29 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $74.86 | 2023-2024 | Tavalisse, Rezlidhia |
| Fennec Pharmaceuticals, INC. | $71.59 | 2024-2025 | Pedmark, Fyarro |
| Regeneron Healthcare Solutions, INC. | $68.36 | 2025 | Libtayo |
| Geron Corporation | $63.76 | 2024-2025 | Rytelo |
| Adc Therapeutics America, INC. | $57.72 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $52.37 | 2024-2025 | Somatuline Depot, Onivyde |
| Genzyme Corporation | $50.66 | 2022-2023 | |
| Csl Behring | $48.89 | 2021-2025 | Afstyla, Idelvion |
| Beigene USA, INC. | $46.72 | 2024 | Tevimbra |
| Mirati Therapeutics, INC. | $44.32 | 2023-2024 | Krazati |
| G1 Therapeutics, INC. | $41.01 | 2023 | Cosela |
| Myovant Sciences INC. | $39.59 | 2021-2022 | |
| Novo Nordisk INC | $39.12 | 2024-2025 | Novoseven, Rebinyn, Novoeight |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.16 | 2021-2022 | |
| Kyowa Kirin, INC. | $32.18 | 2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $29.33 | 2023-2024 | Xarelto |
| Genmab U.S., INC. | $29.27 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $24.33 | 2024 | |
| Syndax Pharmaceuticals, INC. | $23.89 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.64 | 2023 | Qinlock |
| Cti Biopharma Corp. | $20.75 | 2023 | Vonjo |
| Exelixis INC. | $20.00 | 2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $19.77 | 2022 | |
| Foundation Medicine, INC. | $18.38 | 2023 | |
| Global Blood Therapeutics, INC. | $18.16 | 2021 | |
| Ge Healthcare | $17.33 | 2022 | |
| Iovance Biotherapeutics, INC. | $16.49 | 2025 | Amtagvi |
| Shield Therapeutics INC | $15.56 | 2024 | |
| Eusa Pharma (US) LLC | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Doheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.